Indications
Atopic dermatitis (AD) Nemluvio is indicated for the treatment of moderate-to-severe atopic dermatitis in patients aged 12 years and older who are candidates for systemic therapy. Prurigo nodularis (PN) Nemluvio is indicated for the treatment of adults with moderate-to-severe prurigo nodularis who are candidates for systemic therapy.
Composition
- Active substance
- nemolizumab
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- Nemluvio
- Active substance
- nemolizumab
- ATC code
- D11AH12
- Group
- Dermatologicals
- Therapeutic area
- Dermatitis, Atopic, Prurigo
- Marketing authorisation holder
- Galderma International